ATE488519T1 - Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten - Google Patents

Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Info

Publication number
ATE488519T1
ATE488519T1 AT06793584T AT06793584T ATE488519T1 AT E488519 T1 ATE488519 T1 AT E488519T1 AT 06793584 T AT06793584 T AT 06793584T AT 06793584 T AT06793584 T AT 06793584T AT E488519 T1 ATE488519 T1 AT E488519T1
Authority
AT
Austria
Prior art keywords
ylcarbonylazaspiro
indol
derivatives
receptor antagonists
vasopressin receptor
Prior art date
Application number
AT06793584T
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE488519T1 publication Critical patent/ATE488519T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06793584T 2005-09-28 2006-09-18 Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten ATE488519T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108966 2005-09-28
PCT/EP2006/066441 WO2007039438A1 (en) 2005-09-28 2006-09-18 Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE488519T1 true ATE488519T1 (de) 2010-12-15

Family

ID=37156049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06793584T ATE488519T1 (de) 2005-09-28 2006-09-18 Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Country Status (17)

Country Link
US (1) US7790752B2 (de)
EP (1) EP1931680B1 (de)
JP (1) JP4908513B2 (de)
KR (1) KR101018934B1 (de)
CN (1) CN101273046B (de)
AR (1) AR057136A1 (de)
AT (1) ATE488519T1 (de)
AU (1) AU2006298828B2 (de)
BR (1) BRPI0616618A2 (de)
CA (1) CA2623715A1 (de)
DE (1) DE602006018334D1 (de)
ES (1) ES2354909T3 (de)
IL (1) IL189981A (de)
RU (1) RU2418801C2 (de)
TW (1) TWI327571B (de)
WO (1) WO2007039438A1 (de)
ZA (1) ZA200802339B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
KR101050558B1 (ko) 2006-12-08 2011-07-19 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서 작용하는 인돌
CN101838269B (zh) * 2009-03-18 2012-09-26 中国人民解放军军事医学科学院毒物药物研究所 1,3,8-三氮杂-螺[4.5]癸烷-4-酮类化合物及其医药用途
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
WO2017005583A1 (en) 2015-07-03 2017-01-12 F. Hoffmann-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors
EP3414247B1 (de) 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinone als ddr1-hemmer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769578B2 (ja) * 1989-10-13 1998-06-25 大塚製薬株式会社 バソプレシン拮抗剤
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
HU225703B1 (en) * 1999-07-15 2007-06-28 Sanofi Aventis Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives
BR0306309A (pt) * 2002-09-09 2004-10-19 Janssen Pharmaceutica Nv Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1
CA2532059A1 (en) * 2003-05-23 2004-12-02 Zealand Pharma A/S Triaza-spiro compounds as nociceptin analogues and uses thereof
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
BRPI0612988A2 (pt) * 2005-07-14 2010-12-14 Hoffmann La Roche derivados de indol-3-il-carbonil-espiro-piperidina como antagonistas de receptor v1a
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
JP2010511654A (ja) * 2006-12-07 2010-04-15 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ピペリジン誘導体

Also Published As

Publication number Publication date
EP1931680B1 (de) 2010-11-17
IL189981A0 (en) 2008-08-07
KR101018934B1 (ko) 2011-03-02
AU2006298828B2 (en) 2011-12-01
WO2007039438A1 (en) 2007-04-12
CN101273046A (zh) 2008-09-24
AU2006298828A1 (en) 2007-04-12
BRPI0616618A2 (pt) 2011-06-28
JP4908513B2 (ja) 2012-04-04
ZA200802339B (en) 2009-10-28
CN101273046B (zh) 2011-05-25
AR057136A1 (es) 2007-11-21
CA2623715A1 (en) 2007-04-12
US7790752B2 (en) 2010-09-07
DE602006018334D1 (de) 2010-12-30
EP1931680A1 (de) 2008-06-18
ES2354909T3 (es) 2011-03-21
RU2008110409A (ru) 2009-11-10
TWI327571B (en) 2010-07-21
US20070072888A1 (en) 2007-03-29
JP2009510010A (ja) 2009-03-12
TW200804392A (en) 2008-01-16
KR20080049780A (ko) 2008-06-04
IL189981A (en) 2012-09-24
RU2418801C2 (ru) 2011-05-20

Similar Documents

Publication Publication Date Title
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE413874T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ATE545633T1 (de) Als vasopressinantagonisten geeignete benzazepinderivate
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
ATE512966T1 (de) Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
ATE537144T1 (de) Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1931680

Country of ref document: EP